All In Biotech

Drug Trial Radar · NCT07507838

Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV913 Capsules

Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV913 Capsules in Chinese Healthy Participants

Last checked: Nov 19, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Apr 13, 2026

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Vigonvita Life SciencesIndustry
Sponsor type
Industry
First posted
Apr 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a single-center, randomized, double-blind, placebo-controlled, dose-escalation trial to assess the safety, tolerability, pharmacokinetics (PK) of multiple doses of VV913 in Chinese healthy adult participants.

Conditions

  • Healthy Volunteers

Interventions

  • VV913 4mg groupDrug

    6 participants will receive VV913 4mg orally; 2 participants will receive placebo orally.

  • VV913 8mg groupDrug

    6 participants will receive VV913 8mg orally; 2 participants will receive placebo orally.

  • VV913 15mg groupDrug

    6 participants will receive VV913 15mg orally; 2 participants will receive placebo orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse EventsTime frame: Baseline to 6 days after the last administration
  2. CmaxTime frame: Baseline to 72 hours after the last administration
  3. AUC0-∞Time frame: Baseline to 72 hours after the last administration
  4. TmaxTime frame: Baseline to 72 hours after the last administration
  5. t1/2Time frame: Baseline to 72 hours after the last administration
  6. Apparent Clearance Rate(CL/F)Time frame: Baseline to 72 hours after the last administration
  7. Vd/FTime frame: Baseline to 72 hours after the last administration
  8. λzTime frame: Baseline to 72 hours after the last administration
  9. AUC0-24hTime frame: Baseline to 72 hours after the last administration
  10. mean Resident TimeTime frame: Baseline to 72 hours after the last administration
  11. RacTime frame: Baseline to 72 hours after the last administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.